BioCryst/$BCRX
1D1W1MYTD1Y5YMAX
Capital at risk
About BioCryst
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
- Ticker
- $BCRX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 435
- Headquarters
- Durham, United States
- Website
- www.biocryst.com
BioCryst Metrics
BasicAdvanced
$2.1B
-
-$1.68
0.56
-
Price and volume
Market cap
$2.1B
Beta
0.56
52-week high
$11.22
52-week low
$6.00
Average daily volume
3.8M
Financial strength
Current ratio
2.321
Quick ratio
2.219
Long term debt to equity
-1.739
Total debt to equity
-1.842
Interest coverage (TTM)
5.70%
Profitability
EBITDA (TTM)
433.047
Gross margin (TTM)
77.39%
Net profit margin (TTM)
-40.90%
Operating margin (TTM)
45.63%
Effective tax rate (TTM)
-0.91%
Revenue per employee (TTM)
$2,160,000
Management effectiveness
Return on assets (TTM)
52.86%
Return on equity (TTM)
87.84%
Valuation
Price to revenue (TTM)
1.991
Price to book
-4.59
Price to tangible book (TTM)
-4.59
Price to free cash flow (TTM)
5.015
Free cash flow yield (TTM)
19.94%
Free cash flow per share (TTM)
1.627
Growth
Revenue change (TTM)
68.72%
Earnings per share change (TTM)
840.75%
3-year revenue growth (CAGR)
45.30%
10-year revenue growth (CAGR)
43.62%
3-year earnings per share growth (CAGR)
9.03%
10-year earnings per share growth (CAGR)
5.52%
What the Analysts think about BioCryst
Analyst ratings (Buy, Hold, Sell) for BioCryst stock.
Analyst projections of the future price of BioCryst stock.
Bulls say / Bears say
BioCryst delivered strong second-quarter execution, with total revenue of $218.3 million, ORLADEYO revenue of $158.2 million and operating profit of $98.5 million; it also raised 2026 total-revenue guidance to $690–$715 million. (BioCryst)
ORLADEYO’s addressable market is expanding through pediatric formulations: BioCryst began shipping oral pellets for children in August and announced Japanese approval for pediatric hereditary-angioedema patients, creating additional opportunities for patient and prescription growth. (BioCryst)
The Astria acquisition and navenibart program provide a potentially meaningful second HAE growth driver beyond ORLADEYO, with ALPHA-ORBIT pivotal enrollment completed and the company maintaining a focused late-stage development strategy. (BioCryst)
BioCryst remains heavily dependent on ORLADEYO: management’s 2026 guidance calls for $625–$645 million of ORLADEYO revenue, implying only modest growth from 2025’s $601.8 million despite the product accounting for most operating revenue. (BioCryst)
The June 2026 decision to discontinue internal discovery programs and close the Birmingham research facility narrows BioCryst’s internally generated pipeline and increases reliance on external business development to replenish future growth. (BioCryst)
Navenibart remains a clinical and regulatory risk: although enrollment in the pivotal ALPHA-ORBIT study was completed, approval, launch timing and commercial uptake are still uncertain, and BioCryst explicitly warns that development programs may fail or face delays. (BioCryst)
Data summarised monthly by Lightyear AI. Last updated on 10 Sept 2026.
BioCryst Financial Performance
Revenues and expenses
BioCryst Earnings Performance
Company profitability
Upcoming events
No upcoming events
BioCryst News
AllArticlesVideos
Funds containing BioCryst
AllUSDEURGBP
Fund name | Fund size | $BCRX weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.22% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.22% |
iShares Healthcare Innovation£DRDR | £1B | 0.22% |
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.14% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.14% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.